Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers

Crizotinib is an effective drug for patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), but upon treatment, the tumors inevitably become crizotinib resistant in time. The resistance mechanisms are only partly understood. In this study, we aim to identify gene...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Main Authors: Wei, Jiacong, van der Wekken, Anthonie J., Saber, Ali, Terpstra, Miente M., Schuuring, Ed, Timens, Wim, Hiltermann, T. Jeroen N., Groen, Harry J. M., van den Berg, Anke, Kok, Klaas
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5789360/
https://ncbi.nlm.nih.gov/pubmed/29300322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10010010
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares